Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analysts rate Dyne Therapeutics “Moderate Buy,” with 12 buy ratings, two strong-buy ratings, one hold and two sells. The average 12-month price target is $33.07, with recent targets ranging from $30 to $47.
• Insider activity was mixed: a director purchased $40,000 of stock, while insiders sold 2.6 million shares worth approximately $65.4 million during the last quarter. Institutional investors own 96.68% of the company.
• Dyne shares opened at $16.64, below their 50-day and 200-day moving averages, while the company reported a quarterly loss of $1.08 per share versus the $0.75 expected loss. Dyne is developing genetic medicines for neuromuscular diseases, including DYNE-101 and DYNE-251.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been given an average rating of "Moderate Buy" by the seventeen brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $33.07.

A number of research firms recently issued reports on DYN. Raymond James Financial reaffirmed a "strong-buy" rating and set a $37.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 8th. TD Cowen initiated coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a "buy" rating for the company. Chardan Capital reiterated a "buy" rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. Royal Bank Of Canada cut their target price on Dyne Therapeutics from $35.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, September 9th. Finally, Piper Sandler restated an "overweight" rating and issued a $47.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 29th.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Brian S. Posner acquired 2,500 shares of the business's stock in a transaction that occurred on Friday, October 2nd. The shares were bought at an average cost of $16.00 per share, with a total value of $40,000.00. Following the completion of the acquisition, the director directly owned 27,000 shares in the company, valued at $432,000. This represents a 10.20% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jason P. Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares in the company, valued at $10,723,650. This represents a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,598,706 shares of company stock worth $65,432,671 over the last quarter. 9.46% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DYN. GAMMA Investing LLC lifted its holdings in shares of Dyne Therapeutics by 63.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,882 shares of the company's stock valued at $30,000 after purchasing an additional 729 shares during the last quarter. NewEdge Advisors LLC acquired a new position in Dyne Therapeutics during the second quarter valued at $300,000. Nykredit A S purchased a new stake in shares of Dyne Therapeutics in the second quarter worth about $113,000. Moore Capital Management LP boosted its position in Dyne Therapeutics by 288.2% in the 2nd quarter. Moore Capital Management LP now owns 305,794 shares of the company's stock worth $6,792,000 after purchasing an additional 227,029 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new stake in Dyne Therapeutics during the second quarter worth $222,000. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $16.64 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics has a 1 year low of $13.73 and a 1 year high of $27.31. The stock's 50 day simple moving average is $21.56 and its two-hundred day simple moving average is $20.47. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -5.00 and a beta of 1.12.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, equities analysts anticipate that Dyne Therapeutics will post -3.59 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company's research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne's development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.